Data from questionnaires given to type 1 and type 2 diabetes patients from an outpatient clinic is providing insight into how the COVID-19 pandemic has impacted diabetes management.
Results of a phase 3b trial suggest testosterone treatment could prevent the development of diabetes in men with low serum testosterone levels.
An analysis of children from the Avon Longitudinal Study of Parents and Children is providing insight into the potential for increased risk of mental health disorders among patients with high insulin levels or high BMI trajectory as a child.
The SOLOIST-WHF trial indicates that SGLT2 inhibition may lead to an overall reduction in cardiovascular-related deaths and hospitalizations.
A systematic review and meta-analysis of 23 trials suggest adhering to a low carbohydrate diet for a 6-month period could facilitate remission of diabetes and lead to reductions in body weight.
A new study finds benefit to hemoglobin A1c reductions made following conception.
An analysis of data from questionnaires sent to more than 400 patients from a diabetes clinic in Europe gives insight into the impact of lockdown measures on body weight, HbA1c control, and perceived levels of stress and anxiety.
The study finds that individuals with mothers who had pregestational diabetes had a 2.3-fold increased risk of MS compared to those with non-diabetic mothers.
Obese or overweight men participating in a lifestyle-based program had lower rates of diabetes after 2 years when also given testosterone therapy, a new study finds.
A double-blind, placebo-controlled trial is providing insight into the effects of saccharin use on the development of diabetes and glucose absorption in healthy patients.
An analysis of patients from 52 clinical sites details an apparent increase in risk of being hospitalized for diabetic ketoacidosis after contracting COVID-19 among Black patients compared to White patients.
If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.
An analysis of OCT and OCTA scans from 129 diabetics suggests structural and vascular abnormalities of the retina can help predict cognitive decline in patients with type 1 diabetes.
An analysis of 7 AI algorithms for detecting diabetic retinopathy is shedding light on variability in outcomes using the various algorithms that have become available in recent years.
The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.
The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.
The US FDA announced the approval of the first generic drug for the treatment of severe hypoglycemia with the approval of the glucagon for injection USP, 1 mg/vial.
This article features the top 5 stories in Endocrinology Network's coverage of diabetes management in 2020.
Dr. Melissa Young, an endocrinologist, reflects on her experiences during 2020 as part of the My Year in COVID-19 feature series.
Experts in diabetes provide their perspective on various facets of diabetes management including the use of insulin pumps.
A retrospective analysis of more than 7k patients from the ACCORD trial suggests intensive blood pressure and intensive blood glucose control could reduce the risk of cardiovascular autonomic neuropathy in diabetics.
An analysis of more than 7k patients with CAN data from the ACCORD trial suggest intensive blood pressure and blood glucose control could reduce risk of cardiovascular autonomic neuropathy.
A randomized trial sponsored by the National Eye Institute is comparing the effects of a surgical vs anti-VEGF therapy in patients with proliferative diabetic retinopathy.
An analysis of more than 25 studies with more than 1 million patients is giving an overview of how the timing of a diabetes diagnosis can impact risk of complications later in life.
Amputations have increased 30% among diabetic patients since the pandemic began.
